Literature DB >> 11733975

Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study.

T Riman1, P W Dickman, S Nilsson, N Correia, H Nordlinder, C M Magnusson, I R Persson.   

Abstract

OBJECTIVE: Borderline ovarian tumors have a favorable prognosis. Previous epidemiological studies indicate common risk factors for invasive epithelial ovarian cancers and borderline tumors, but it remains unresolved whether these tumors are precursors of invasive cancers or a separate disease entity. The objective of this population-based case-control study conducted in 1993-1995 was to examine reproductive and other factors in relation to the risk of borderline ovarian tumors.
METHODS: Subjects were 193 histologically verified incident epithelial borderline tumor cases and 3899 randomly selected controls aged 50-74 years, whose data were collected through mailed questionnaires. Risk estimates were calculated by unconditional logistic regression.
RESULTS: Ever parous women were at reduced risk, with odds ratios of 0.44 (95% confidence interval (CI) 0.26-0.75) for serous and 0.63 (95% CI 0.34-1.19) for mucinous tumors. No clear trends emerged for age at first birth, at menarche, and at menopause. Lactation reduced tumor risk. Oral contraceptive ever use conferred no protection, with odds ratios of 1.40 (95% CI 0.87-2.26) for serous and 1.04 (95% CI 0.61-1.79) for mucinous tumors. The odds ratio for serous tumors following unopposed estrogen ever use was 2.07 (95% CI 1.08-3.95), whereas no risk increase appeared with estrogens supplemented by cyclic or continuous progestins. Mucinous tumors were not associated with hormone replacement therapy. The odds ratio for serous tumors in the highest category of body mass index was 6.47 (95% CI 3.09-13.5).
CONCLUSIONS: Increasing parity and lactation reduce the risk of borderline ovarian tumors in women aged 50-74, while no protection follows oral contraceptive use. Hormonal situations such as unopposed estrogen use and obesity, where estrogens are not counteracted by progestins, may increase the risk of serous tumors. (c)2001 Elsevier Science.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11733975     DOI: 10.1006/gyno.2001.6451

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  23 in total

1.  Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies.

Authors:  Nan-Nan Luan; Qi-Jun Wu; Ting-Ting Gong; Emily Vogtmann; Yong-Lai Wang; Bei Lin
Journal:  Am J Clin Nutr       Date:  2013-08-21       Impact factor: 7.045

2.  Management of Borderline Ovarian Tumors-Still a Gray Zone.

Authors:  Nidhi Nayyar; Prerna Lakhwani; Ashish Goel; Pankaj Kr Pande; Kapil Kumar
Journal:  Indian J Surg Oncol       Date:  2017-08-25

Review 3.  Diagnosis, treatment, and follow-up of borderline ovarian tumors.

Authors:  Daniela Fischerova; Michal Zikan; Pavel Dundr; David Cibula
Journal:  Oncologist       Date:  2012-09-28

Review 4.  Association between Cigarette Smoking and Histotype-Specific Epithelial Ovarian Cancer: A Review of Epidemiologic Studies.

Authors:  Aili Zhou; Albina N Minlikeeva; Sadat Khan; Kirsten B Moysich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-05-01       Impact factor: 4.254

Review 5.  Current understanding of risk factors for ovarian cancer.

Authors:  Thanasak Sueblinvong; Michael E Carney
Journal:  Curr Treat Options Oncol       Date:  2009-07-15

6.  Epidemiologic correlates of ovarian cortical inclusion cysts (CICs) support a dual precursor pathway to pelvic epithelial cancer.

Authors:  Ann K Folkins; Aasia Saleemuddin; Leslie A Garrett; Judy E Garber; Michael G Muto; Shelley S Tworoger; Christopher P Crum
Journal:  Gynecol Oncol       Date:  2009-07-16       Impact factor: 5.482

7.  Gestational age and fetal growth in relation to maternal ovarian cancer risk in a Swedish cohort.

Authors:  Lorelei A Mucci; Paul W Dickman; Mats Lambe; Hans-Olov Adami; Dimitrios Trichopoulos; Tomas Riman; Chung-Cheng Hsieh; Sven Cnattingius
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-09       Impact factor: 4.254

8.  Use of nonsteroidal antiinflammatory agents and incidence of ovarian cancer in 2 large prospective cohorts.

Authors:  Simone P Pinheiro; Shelley S Tworoger; Daniel W Cramer; Bernard A Rosner; Susan E Hankinson
Journal:  Am J Epidemiol       Date:  2009-04-02       Impact factor: 4.897

Review 9.  Increased ovarian cancer risk associated with menopausal estrogen therapy is reduced by adding a progestin.

Authors:  Celeste Leigh Pearce; Karine Chung; Malcolm C Pike; Anna H Wu
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

10.  Age at menarche and risk of ovarian cancer: a meta-analysis of epidemiological studies.

Authors:  Ting-Ting Gong; Qi-Jun Wu; Emily Vogtmann; Bei Lin; Yong-Lai Wang
Journal:  Int J Cancer       Date:  2012-12-13       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.